Hazard Information | Back Directory | [Uses]
Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC)[1]. | [in vivo]
Efungumab (2 mg/kg, i.p., daily for 3 days) significantly decreases mean organ colony counts and increases negative liver biopsies for many of the isolates in CD1 mice models of disseminated c. albicans disease[2]. Animal Model: | CD1 mice models of disseminated c. albicans disease[2] | Dosage: | 2 mg/kg, daily for 3 days | Administration: | Intraperitoneal injection (i.p.) | Result: | Decreased mean organ colony counts and increased negative liver biopsies for many of the isolates. |
| [References]
[1] Karwa R, et al. Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23. DOI:10.1345/aph.1M218 [2] Cowen LE, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2818-23. DOI:10.1073/pnas.0813394106 |
|
Company Name: |
LGM Pharma
|
Tel: |
1-(800)-881-8210 |
Website: |
www.lgmpharma.com |
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 18108604356 |
Website: |
www.biolabreagent.com/ |
Company Name: |
Cell Sciences
|
Tel: |
9785721070 |
Website: |
www.cellsciences.com |
Company Name: |
Wonda Science
|
Tel: |
+1 (514) 581-6866 |
Website: |
www.wondascience.com |
|